Experimental Therapeutics Poster Discusson on Tumor Targeting

Milas, Luka¹, Koto, Masashi^*,1, Valdecanas, David¹, Mason, Kathy¹, Hunter, Nancy¹, Fan, Zhen², Fang, Fu-Min¹, Ang, Kian³, ¹ Experimental Radiation Oncology and Division of Radiation Oncology, Houston, TX, USA² Experimental Therapeutics, Houston, TX, USA³ Division of Radiation Oncology, Houston, TX, USA
(PD010) C225-induced enhancement of tumor radioresponse: Influence of timing of C225 administration.

Cowen, Rachel¹, Wind, Natasha¹, Telfer, Brian¹, Stratford, Ian¹, Papadopoulou, Maria^*,2, Bloomer, William², Williams, Kaye¹, ¹ School of Pharmacy and Pharmaceutical Sciences, Manchester, Greater Manchester, UK² Department of Radiation Medicine, Evanston, Illinois, USA
(PD011) Exploiting cytochrome p450 reductase-mediated enhancement of NLCQ-1 hypoxic cytotoxicity for use in combination with radiotherapy.

Moeller, Benjamin^*,1, Dreher, Matthew², Rabbani, Zahid³, Schroeder, Thies³, Cao, Yiting¹, Dewhirst, Mark^{1, 2, 3}, ¹ Department of Pathology, Durham, NC, USA² Department of Biomedical Engineering, Durham, NC, USA³ Department of Radiation Oncology, Durham, NC, USA
(PD012) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.

Ponce, Ana^*,1, Viglianti, Benjamin¹, Yarmolenko, Pavel², Bally, Marcel³, Woo, Janet³, Dewhirst, Mark², ¹ Dept of Biomedical Engineering, Durham, NC² Dept of Radiation Oncology, Durham, NC³ BC Cancer Agency, Vancouver, BC
(PD013) Liposomal drug distribution and anti-tumor effect: drug dose painting with hyperthermia using MRI.

Wiedenmann, Nicole^{*,1, 2}, Neal, Robert¹, Hunter, Nancy¹, Raju, Uma¹, Milas, Luka¹, Mason, Kathy¹, ¹ Department of Experimental Radiation Oncology, Houston, TX, USA² Department of Radiation Oncology, Munich, D, Germany
(PD014) In vivo interaction of single dose radiation with G3139, a Bcl-2 antisense oligonucleotide.

Xu, Mai¹, Wu, M², Crooks, Peter³, Freeman, Michael⁴, Roti Roti, Joseph^*,1, ¹ Radiation and Cancer Biology Division, St. Louis, MO, USA² Department of Radiation Oncology, Taipei, Taiwan, China³ College of Pharmacy, Lexington, KY, USA⁴ Department of Radiation Oncology, Nashville, TN
(PD015) Radiosensitization by the combination of 41°C hyperthermia and indomethacin analogs.

Burd, Randy ^*,1, Lavorgna, Stephanie ¹, Thangasamy, Thilakavathy¹, Kong, Xianguo¹, Lenaz, Luigi ², Chawla, Shanta², Reddy, Guru², Wachsberger, Phylis ¹, Dicker, Adam¹, ¹ Radiation Oncology, Philadelphia, PA, USA² Oncology, Irvine, CA, USA
(PD016) Enhancement of radiation response in tumors by the bioreductive agent Apaziquone (EO9, EOquin).

Krause, Mechthild^*,1, Ostermann, Gernot¹, Petersen, Cordula¹, Harstrick, Andreas², Yaromina, Ala¹, Thames, Howard³, Baumann, Michael¹, ¹ Dept. of Radiation Oncology, Dresden, Saxony, Germany² Merck KG aA, Darmstadt, Hessen, Germany³ Dept. of Biomathematics, Houston, Texas, USA
(PD017) Targeting of the EGFR by C225 improves local control of FaDu hSCC by decreased repopulation and increased reoxygenation during fractionated irradiation.